ES2494921T3 - Anticuerpo que sustituye la función del factor VIII de coagulación sanguínea - Google Patents

Anticuerpo que sustituye la función del factor VIII de coagulación sanguínea Download PDF

Info

Publication number
ES2494921T3
ES2494921T3 ES06730769.4T ES06730769T ES2494921T3 ES 2494921 T3 ES2494921 T3 ES 2494921T3 ES 06730769 T ES06730769 T ES 06730769T ES 2494921 T3 ES2494921 T3 ES 2494921T3
Authority
ES
Spain
Prior art keywords
coagulation factor
a44fr
pcagg
a44lr3
a44lf3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES06730769.4T
Other languages
English (en)
Inventor
Tetsuo Kojima
Kunihiro Hattori
Tetsuhiro Soeda
Taro Miyazaki
Hiroyuki Saito
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37086871&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2494921(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2494921T3 publication Critical patent/ES2494921T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Un anticuerpo biespecífico que puede sustituir funcionalmente al factor VIII de coagulación y que presenta la actividad para mejorar la activación del factor X, que comprende: un primer dominio que reconoce al factor de coagulación IX y/o al factor de coagulación IX activado; y un segundo dominio que reconoce al factor de coagulación X, donde el primer dominio comprende un primer polipéptido que comprende la cadena H de un anticuerpo contra el factor de coagulación IX y/o el factor de coagulación IX activado; el segundo dominio comprende un segundo polipéptido que comprende la cadena H de un anticuerpo contra el factor de coagulación X; y tanto el primero como el segundo dominio comprenden un tercer polipéptido que comprende una cadena L compartida en común de un anticuerpo contra el factor de coagulación IX, el factor de coagulación IX activado o el factor de coagulación X, donde el tercer polipéptido comprende un sitio de unión a antígenos que comprende las CDR1, 2 y 3 seleccionadas individualmente de CDR1, 2 y 3 de cada cadena L de dos o más anticuerpos;

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26
imagen27
imagen28
imagen29
imagen30
E06730769
22-08-2014
GAAGCGATCAGGGACTCCACTGTACCGGTAGGATGCCGAGTAAATCAGTAGTTTAGG B26LF4_A44fr (SEQ ID NO: 61) CTGGCAGATTATCTCTGTCAGCAATATAACAGCTATCCACTCACGTTCGGTGGTGGGA CC A69LR1_A44fr (SEQ ID NO: 62)
5 GGCTACAGCAGTACTCACATCCTGACTGGCCTTGCAGGTGATGCTGACCCTGTCTCCT ACTGATGTGGA A5OLF4_A44fr (SEQ ID NO: 63) CTGGCAGATTATCTCTGTCAGCAATATAGCAGCTATTTAACGTTCGGTGGTGGGACC scback (SEQ ID NO: 64) TTACTCGCGGCCCAGCCGGCCATGGCGGACTACAAAG
10 scfor (SEQ ID NO: 65) GGAATTCGGCCCCCGAG Se mezcló 1 µL de cada oligo ADN sintetizado preparado a 10 µM en la combinación que se muestra en la tabla 1, y
se prepararon 45 µL de las soluciones de reacción que comprenden 1x de tampón agregado de enzimas, 0,33 mM de dNTPs, 2,5 unidades de Proof Start Polymerase (Qiagen) o LATaq (TAKARA). Después de calentar a 94°C
15 durante 5 minutos, se llevaron a cabo 7 ciclos de reacciones a 94°C durante un minuto y 63 °C durante 4 minutos, posteriormente se agregaron 5 µL cada solución de 5 µM de scback y 5 µM de scfor, y se llevaron a cabo 30 ciclos de reacciones a 94°C durante 30 segundos, 55°C durante 30 segundos, y 72°C durante 30 segundos para amplificar el gen VL.
BBA :
B26LR1_A44fr B26LR2_A44fr A44LF4 A44LF1 A44LF2 A44LF3 A44LR3 A44LR4
BAA :
B26LR1_A44fr A44LR2 A44LF4 A44LF1 A44LF2 A44LF3 A44LR3 A44LR4
ABA :
A44LR1 B26LR2_A44fr A44LF4 A44LF1 A44LF2 A44LF3 A44LR3 A44LR4
AAA :
A44LR1 A44LR2 A44LF4 A44LF1 A44LF2 A44LF3 A44LR3 A44LR4
AAa :
A44LR1 A44LR2 A50LF4_A44fr A44LF1 A44LF2 A44LF3 A44LR3 A44LR4
BAa :
B26LR1_A44fr A44LR2 A50LF4_A44fr A44LF1 A44LF2 A44LF3 A44LR3 A44LR4
ABa :
A44LR1 B26LR2_A44fr A50LF4_A44fr A44LF1 A44LF2 A44LF3 A44LR3 A44LR4
BBa :
B26LR1_A44fr B26LR2_A44fr A50LF4_A44fr A44LF1 A44LF2 A44LF3 A44LR3 A44LR4
aAA :
A69LR1_A44fr A44LR2 A44LF4 A44LF1 A44LF2 A44LF3 A44LR3 A44LR4
aBA :
A69LR1_A44fr B26LR2_A44fr A44LF4 A44LF1 A44LF2 A44LF3 A44LR3 A44LR4
BBA(G) :
B26LR1_A44fr B26LR2_A44fr A44LF4 A44LF1 A44LF2 A44LF3 A44LR3 A44LR4Gly
BAA(G) :
B26LR1_A44fr A44LR2 A44LF4 A44LF1 A44LF2 A44LF3 A44LR3 A44LR4Gly
ABA(G) :
A44LR1 B26LR2_A44fr A44LF4 A44LF1 A44LF2 A44LF3 A44LR3 A44LR4Gly
AAA(G) :
A44LR1 A44LR2 A44LF4 A44LF1 A44LF2 A44LF3 A44LR3 A44LR4Gly
AAa(G) :
A44LR1 A44LR2 A50LF4_A44fr A44LF1 A44LF2 A44LF3 A44LR3 A44LR4Gly
Baa(G) :
B26LR1_A44fr A44LR2 A50LF4_A44fr A44LF1 A44LF2 A44LF3 A44LR3 A44LR4Gly
ABa(G) :
A44LR1 B26LR2_A44fr A50LF4_A44fr A44LF1 A44LF2 A44LF3 A44LR3 A44LR4Gly
BBa(G) :
B26LR1_A44fr B26LR2_A44fr A50LF4_A44fr A44LF1 A44LF2 A44LF3 A44LR3 A44LR4Gly
aAA(G) :
A69LR1_A44fr A44LR2 A44LF4 A44LF1 A44LF2 A44LF3 A44LR3 A44LR4Gly
aBA(G) :
A69LR1_A44fr B26LR2_A44fr A44LF4 A44LF1 A44LF2 A44LF3 A44LR3 A44LR4Gly
32
E06730769
22-08-2014
Después de la realización de la PCR, los productos se purificaron a partir de todas las soluciones de la reacción mediante el uso del kit de purificación de PCR QIAquick (Qiagen) a través del procedimiento descrito en el manual de instrucciones adjunto, y se eluyeron mediante el uso de agua esterilizada. Después de que se digirieron los fragmentos con la enzima de restricción Sfi I (TOYOBO), se sometieron a electroforesis en gel de agarosa al 2%. 5 Los fragmentos de amplificación que tienen aproximadamente 0,4 kb se purificaron mediante el uso del kit de extracción en gel QIAquick (QIAGEN) a través del procedimiento descrito en el manual de instrucciones adjunto y se eluyeron mediante el uso de agua esterilizada. Los fragmentos obtenidos se ligaron mediante el uso de alta ligación (TOYOBO) con el vector de expresión de cadena L descrito anteriormente pCAGG-κ que se había digerido con Sfi I. Se utilizó parte de cada solución de reacción para transformar la cepa DH5 α E. coli (TOYOBO). Se determinaron las 10 secuencias de nucleótidos y se confirmaron mediante el uso del kit de secuenciación BigDye Terminator Cycle (Applied Biosystems) con el secuenciador de ADN ABI PRISM 3700 DNA Sequencer (Applied Biosystems) de conformidad con el procedimiento descrito en el manual de instrucciones adjunto. pCAGG-A44BBA se obtuvo mediante inserción del fragmento BBA y otros vectores de expresión se obtuvieron de forma similar mediante inserción de otros fragmentos VL. Las secuencias de región variable de anticuerpos correspondientes se describen 15 en las siguientes SEQ ID NO. Tabla 2
SEQ ID NO de nucleótidos:
SEQ ID NO de aminoácidos:
(1) AAA
(pAGG-A44L) 66 67
(2) BBA
(pCAGG-A44BBA) 68 69
(3) BAA
(pCAGG-A44BAA) 70 71
(4) ABA
(pCAGG-A44ABA) 72 73
(5) AAa
(pCAGG-A44AAa) 74 75
(6) BAa
(pCAGG-A44BAa) 76 77
(7) ABa
(pCAGG-A44ABa) 78 79
(8) BBa
(pCAGG-A44BBa) 80 81
(9) aAA
(pCAGG-A44aAA) 82 83
(10) aBA
(pCAGG-A44aBA) 84 85
(11) AAA (G)
(pCAGG-A44LG) 86 87
(12) BBA (G)
(pCAGG-A44BBAG) 88 89
(13) BAA (G)
(pCAGG-A44BAAG) 90 91
(14) ABA (G)
(pCAGG-A44ABAG) 92 93
(15) AAa (G)
(pCAGG-A44AAaG) 94 95
(16) BAa (G)
(pCAGG-A44BAaG) 96 97
(17) ABa (G)
(pAGG-A44ABaG) 98 99
(18) BBa (G)
(pCAGG-A44BBaG) 100 101
(19) aAA (G)
(pCAGG-A44aAAG) 102 103
(20) aBA (G)
(pAGG-A44aBAG) 104 105

[Ejemplo 19] Preparación de anticuerpos
Las células de la cepa HEK293 derivadas de células de carcinoma renal fetal humanas se suspendieron en medio DMEM (Invitrogen) que contenía FCS al 10% (Moregate), 6 x 106 células se colocaron en platos de 10 cm de 20 diámetro para células adherentes (Coming) y se cultivaron en una incubadora de CO2 (37°C, CO2 al 5%) durante la noche. Cualquiera de los vectores de expresión de cadena L del ejemplo 18, dos tipos del vector de expresión de cadena H (30 µg) de pCAGG-chiB26-g4b y pCAGG-chiA44-g4a o pCAGG-chiA69-g4a del ejemplo 17, y 1,5 mL de medio OPTI-MEMI se agregaron a la mezcla de 60 µL de reactivo de transfección Lipofectamine 2000 (Invitrogen) y 1,5 mL de medio Opti-MEM I (Invitrogen) y se dejó reposar a temperatura ambiente durante 20 minutos, y la mezcla
33
imagen31
imagen32
imagen33
imagen34
imagen35

Claims (1)

  1. imagen1
    imagen2
ES06730769.4T 2005-04-08 2006-03-31 Anticuerpo que sustituye la función del factor VIII de coagulación sanguínea Expired - Lifetime ES2494921T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2005112514 2005-04-08
JP2005112514 2005-04-08
PCT/JP2006/306821 WO2006109592A1 (ja) 2005-04-08 2006-03-31 血液凝固第viii因子の機能代替抗体

Publications (1)

Publication Number Publication Date
ES2494921T3 true ES2494921T3 (es) 2014-09-16

Family

ID=37086871

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06730769.4T Expired - Lifetime ES2494921T3 (es) 2005-04-08 2006-03-31 Anticuerpo que sustituye la función del factor VIII de coagulación sanguínea

Country Status (13)

Country Link
US (15) US20100003254A1 (es)
EP (2) EP2824183B1 (es)
JP (3) JP4917024B2 (es)
CA (2) CA2957144C (es)
CY (1) CY1115702T1 (es)
DK (2) DK1876236T3 (es)
ES (1) ES2494921T3 (es)
NO (1) NO348522B1 (es)
PL (1) PL1876236T3 (es)
PT (1) PT1876236E (es)
SI (1) SI1876236T1 (es)
TW (1) TW200714313A (es)
WO (1) WO2006109592A1 (es)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8597911B2 (en) * 2003-06-11 2013-12-03 Chugai Seiyaku Kabushiki Kaisha Process for producing antibodies
WO2005035753A1 (ja) * 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha 機能蛋白質を代替する二重特異性抗体
US20080075712A1 (en) * 2003-10-14 2008-03-27 Kunihiro Hattori Double Specific Antibodies Substituting For Functional Proteins
TWI544076B (zh) 2005-03-31 2016-08-01 中外製藥股份有限公司 A method of manufacturing a polypeptide that controls assembly
JP5144499B2 (ja) 2006-03-31 2013-02-13 中外製薬株式会社 二重特異性抗体を精製するための抗体改変方法
CA2647846C (en) * 2006-03-31 2016-06-21 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
SG193868A1 (en) * 2007-09-26 2013-10-30 Chugai Pharmaceutical Co Ltd Modified antibody constant region
RU2510400C9 (ru) 2007-09-26 2014-07-20 Чугаи Сейяку Кабусики Кайся Способ модификации изоэлектрической точки антитела с помощью аминокислотных замен в cdr
TWI548418B (zh) * 2007-12-05 2016-09-11 中外製藥股份有限公司 Anti-NR10 / IL-31RA antibody and its use
TW201920257A (zh) 2008-04-11 2019-06-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗原結合分子
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
JP5717624B2 (ja) 2009-03-19 2015-05-13 中外製薬株式会社 抗体定常領域改変体
WO2010107109A1 (ja) 2009-03-19 2010-09-23 中外製薬株式会社 抗体定常領域改変体
TW201041595A (en) 2009-05-15 2010-12-01 Chugai Pharmaceutical Co Ltd Anti-axl antibody
WO2011037158A1 (ja) 2009-09-24 2011-03-31 中外製薬株式会社 抗体定常領域改変体
US8518405B2 (en) 2009-10-08 2013-08-27 The University Of North Carolina At Charlotte Tumor specific antibodies and uses therefor
PL2522724T3 (pl) 2009-12-25 2020-07-13 Chugai Seiyaku Kabushiki Kaisha Sposób modyfikowania polipetydów do oczyszczania multimerów polipeptydowych
TWI505838B (zh) 2010-01-20 2015-11-01 中外製藥股份有限公司 Stabilized antibody solution containing
EP2530109A4 (en) 2010-01-29 2013-08-28 Toray Industries RESIN SHEET BASED ON POLYLACTIC ACID
EP2543730B1 (en) 2010-03-04 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
US9845362B2 (en) 2010-10-08 2017-12-19 The University Of North Carolina At Charlotte Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same
KR101398290B1 (ko) * 2010-11-17 2014-05-22 추가이 세이야쿠 가부시키가이샤 혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
MX349057B (es) 2010-11-30 2017-07-07 Chugai Pharmaceutical Co Ltd Agente terapeutico que induce citotoxicidad.
SG10201509790YA (en) 2010-11-30 2015-12-30 Chugai Pharmaceutical Co Ltd Antigen-Binding Molecule Capable Of Binding To Plurality Of Antigen Molecules Repeatedly
US20140080153A1 (en) 2011-01-07 2014-03-20 Chugai Seiyaku Kabushiki Kaisha Method for improving physical properties of antibody
SG10201609665PA (en) 2011-02-25 2017-01-27 Chugai Pharmaceutical Co Ltd FcɣRIIb-SPECIFIC Fc ANTIBODY
TW201817745A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
MX359775B (es) 2011-10-31 2018-10-10 Chugai Pharmaceutical Co Ltd Molecula enlazada al antigeno que tiene conjugacion regulada entre cadena ligera y cadena pesada.
UA114108C2 (uk) 2012-07-10 2017-04-25 Борд Оф Ріджентс, Дзе Юніверсіті Оф Техас Сістем Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання
ES2668455T3 (es) 2012-09-28 2018-05-18 Chugai Seiyaku Kabushiki Kaisha Método para evaluar la reacción de coagulación sanguínea
TW201536810A (zh) * 2013-07-15 2015-10-01 Novo Nordisk As 結合尿激酶纖維蛋白溶酶原活化物之抗體
AU2014325063B2 (en) 2013-09-27 2019-10-31 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide heteromultimer
EP3126384B1 (en) * 2014-04-01 2020-12-02 Adimab, LLC Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use
TWI831106B (zh) 2014-06-20 2024-02-01 日商中外製藥股份有限公司 用於因第viii凝血因子及/或活化的第viii凝血因子的活性降低或欠缺而發病及/或進展的疾病之預防及/或治療之醫藥組成物
US11554181B2 (en) 2014-09-05 2023-01-17 The University Of North Carolina At Charlotte Tumor specific antibody conjugates and uses therefor
TWI700300B (zh) * 2014-09-26 2020-08-01 日商中外製藥股份有限公司 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
MA40764A (fr) * 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
TWI701435B (zh) 2014-09-26 2020-08-11 日商中外製藥股份有限公司 測定ｆｖｉｉｉ的反應性之方法
WO2016098356A1 (en) 2014-12-19 2016-06-23 Chugai Seiyaku Kabushiki Kaisha Anti-c5 antibodies and methods of use
KR102650420B1 (ko) 2014-12-19 2024-03-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
CN112142844B (zh) 2015-02-05 2025-07-25 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
TWI805046B (zh) 2015-02-27 2023-06-11 日商中外製藥股份有限公司 Il-6受體抗體用於製備醫藥組成物的用途
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
US10787500B2 (en) 2015-04-10 2020-09-29 Adimab, Llc Methods for purifying heterodimeric multispecific antibodies from parental homodimeric antibody species
BR112017016952A2 (pt) 2015-04-17 2018-04-03 F. Hoffmann-La Roche Ag terapia de combinação com fatores de coagulação e anticorpos multiespecíficos
JP2018123055A (ja) * 2015-04-24 2018-08-09 公立大学法人奈良県立医科大学 血液凝固第ｖｉｉｉ因子（ｆｖｉｉｉ）の機能を代替する多重特異性抗原結合分子を含有する、血液凝固第ｘｉ因子（ｆｘｉ）異常症の予防および／または治療に用いられる医薬組成物
US10723793B2 (en) * 2015-06-12 2020-07-28 Ludwig Institute For Cancer Research, Ltd. TGF-β3 specific antibodies and methods and uses thereof
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
WO2017032611A1 (en) * 2015-08-21 2017-03-02 F. Hoffmann-La Roche Ag Method for the reduction of host cell proteins in affinity chromatography
AU2016312909B2 (en) 2015-08-21 2022-12-08 F. Hoffmann-La Roche Ag Method for the reduction of host cell proteins in affinity chromatography
US20200270363A1 (en) 2015-12-25 2020-08-27 Chugai Seiyaku Kabushiki Kaisha Antibody having enhanced activity, and method for modifying same
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
AU2016381992B2 (en) 2015-12-28 2024-01-04 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide
KR20180116215A (ko) 2016-03-14 2018-10-24 추가이 세이야쿠 가부시키가이샤 암의 치료에 이용하기 위한 세포상해 유도 치료제
CR20180554A (es) 2016-04-28 2019-01-10 Chugai Pharmaceutical Co Ltd Preparaciones que contienen anticuerpos
US11098132B2 (en) * 2016-05-16 2021-08-24 Takeda Pharmaceutical Company Limited Anti-factor IX Padua antibodies
EP3492496A4 (en) 2016-07-29 2020-07-29 Chugai Seiyaku Kabushiki Kaisha BISPECIFIC ANTIBODIES PRESENTING AN INCREASED ALTERNATIVE FUNCTIONAL ACTIVITY OF COFACTOR FVIII
MX2019001448A (es) 2016-08-05 2019-09-13 Chugai Pharmaceutical Co Ltd Composicion para profilaxis o tratamiento de enfermedades relacionadas con interleucina 8 (il-8).
AU2017325240B9 (en) 2016-09-06 2025-02-13 Chugai Seiyaku Kabushiki Kaisha Methods of using a bispecific antibody that recognizes coagulation factor IX and/or activated coagulation factor IX and coagulation factor X and/or activated coagulation factor X
PE20191347A1 (es) 2017-02-01 2019-09-30 Novo Nordisk As Anticuerpos procoagulantes
CN110461358A (zh) 2017-03-31 2019-11-15 公立大学法人奈良县立医科大学 可用于预防和/或治疗凝血因子ⅸ异常、包含代替凝血因子ⅷ的功能的多特异性抗原结合分子的药物组合物
EP3620531A4 (en) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
GB201709970D0 (en) * 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
EP4088783A1 (en) 2017-08-01 2022-11-16 Ab Studio Inc. Bispecific antibodies and uses thereof
CN111108202B (zh) 2017-09-29 2024-10-22 中外制药株式会社 具有凝血因子viii(fviii)辅因子功能替代活性的多特异性抗原结合分子及含有所述分子作为活性成分的药物制剂
CN119161488A (zh) 2017-11-01 2024-12-20 中外制药株式会社 具有降低的生物活性的抗体变体和同种型
WO2019096874A1 (en) 2017-11-15 2019-05-23 Novo Nordisk A/S Factor x binders enhancing fx activation
JP7370322B2 (ja) 2018-06-04 2023-10-27 中外製薬株式会社 複合体を検出する方法
FR3082427B1 (fr) 2018-06-14 2020-09-25 Lab Francais Du Fractionnement Combinaison de facteur vii et d'un anticorps bispecifique anti-facteurs ix et x
US11220554B2 (en) 2018-09-07 2022-01-11 Novo Nordisk A/S Procoagulant antibodies
CN117384296A (zh) * 2018-08-01 2024-01-12 诺和诺德股份有限公司 改进的促凝血抗体
US20220064327A1 (en) 2018-12-21 2022-03-03 Kymab Limited Fixaxfx bispecific antibody with common light chain
BR112021014313A2 (pt) 2019-01-21 2021-10-05 Aronora Inc. Anticorpos humanizados inovadores contra o fator xi que tem efeitos anti-trombóticos e anti-inflamatórios e usos dos mesmos
US12463463B2 (en) 2019-01-28 2025-11-04 Ab Therapeutics, Inc. Bispecific antibodies and uses thereof
WO2021070885A1 (ja) 2019-10-11 2021-04-15 中外製薬株式会社 後天性血友病ａの予防および／または治療に用いられる医薬組成物、および当該医薬組成物を含む製品
MX2022003912A (es) 2019-10-11 2022-04-20 Chugai Pharmaceutical Co Ltd Composicion farmaceutica que puede usarse para la prevencion y/o el tratamiento de la hemofilia a adquirida, y producto que comprende la composicion farmaceutica.
JP2023106635A (ja) 2020-04-17 2023-08-02 中外製薬株式会社 二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法
JP7752613B2 (ja) 2020-05-22 2025-10-10 中外製薬株式会社 凝固第ｖｉｉｉ因子（ｆ．ｖｉｉｉ）機能代替活性を有する物質を中和する抗体
WO2025155602A1 (en) 2024-01-16 2025-07-24 Genentech, Inc. Method of treating hemophilia a

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US55092A (en) * 1866-05-29 Improvement in rotary steam-engines
US111406A (en) * 1871-01-31 Pctehs
US76275A (en) * 1868-03-31 Tuttle
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
JPS5837636B2 (ja) * 1980-07-31 1983-08-17 富士通株式会社 半導体記憶装置
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4444878A (en) * 1981-12-21 1984-04-24 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US6010902A (en) * 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
DE3920358A1 (de) * 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
TW212184B (es) * 1990-04-02 1993-09-01 Takeda Pharm Industry Co Ltd
DE69133476T2 (de) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgene Mäuse fähig zur Produktion heterologer Antikörper
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
AU3328493A (en) 1991-12-17 1993-07-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5667988A (en) * 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
ES2242954T3 (es) 1992-03-11 2005-11-16 Powderject Vaccines, Inc. Vacuna genetica para el virus de la inmunodeficiencia.
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5945311A (en) * 1994-06-03 1999-08-31 GSF--Forschungszentrumfur Umweltund Gesundheit Method for producing heterologous bi-specific antibodies
AU701342B2 (en) 1994-07-13 1999-01-28 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin-8
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US20030207346A1 (en) * 1997-05-02 2003-11-06 William R. Arathoon Method for making multispecific antibodies having heteromultimeric and common components
ES2246069T3 (es) * 1997-05-02 2006-02-01 Genentech, Inc. Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos.
US20020062010A1 (en) * 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
DE19725586C2 (de) * 1997-06-17 1999-06-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von Zellpräparaten zur Immunisierung mittels heterologer intakter bispezifischer und/oder trispezifischer Antikörper
EP2363484A3 (en) 1998-04-03 2012-04-25 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (TF) and process of production of the humanized antibody
AT411997B (de) * 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
DE10156482A1 (de) * 2001-11-12 2003-05-28 Gundram Jung Bispezifisches Antikörper-Molekül
AU2003227504A1 (en) * 2002-04-15 2003-10-27 Chugai Seiyaku Kabushiki Kaisha METHOD OF CONSTRUCTING scDb LIBRARY
US7732149B2 (en) * 2002-04-26 2010-06-08 Chugai Seiyaku Kabushiki Kaisha Methods of screening agonistic antibodies
US20050130224A1 (en) * 2002-05-31 2005-06-16 Celestar Lexico- Sciences, Inc. Interaction predicting device
PT1523496E (pt) * 2002-07-18 2011-09-29 Merus B V Produção de misturas de anticorpos de forma recombinante
WO2004065611A1 (ja) * 2003-01-21 2004-08-05 Chugai Seiyaku Kabushiki Kaisha 抗体の軽鎖スクリーニング方法
GB2400851B (en) * 2003-04-25 2004-12-15 Bioinvent Int Ab Identifying binding of a polypeptide to a polypeptide target
US8597911B2 (en) * 2003-06-11 2013-12-03 Chugai Seiyaku Kabushiki Kaisha Process for producing antibodies
US7297336B2 (en) * 2003-09-12 2007-11-20 Baxter International Inc. Factor IXa specific antibodies displaying factor VIIIa like activity
WO2005035753A1 (ja) * 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha 機能蛋白質を代替する二重特異性抗体
US20080075712A1 (en) * 2003-10-14 2008-03-27 Kunihiro Hattori Double Specific Antibodies Substituting For Functional Proteins
TWI263461B (en) * 2003-12-26 2006-10-01 Ind Tech Res Inst Enhanced flexible copper foil structure and fabrication method thereof
US20050266425A1 (en) * 2003-12-31 2005-12-01 Vaccinex, Inc. Methods for producing and identifying multispecific antibodies
TWI544076B (zh) * 2005-03-31 2016-08-01 中外製藥股份有限公司 A method of manufacturing a polypeptide that controls assembly
CA2610987C (en) * 2005-06-10 2013-09-10 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
CA2647846C (en) * 2006-03-31 2016-06-21 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
JP5144499B2 (ja) * 2006-03-31 2013-02-13 中外製薬株式会社 二重特異性抗体を精製するための抗体改変方法

Also Published As

Publication number Publication date
TW200714313A (en) 2007-04-16
US20190359728A1 (en) 2019-11-28
US20180002443A1 (en) 2018-01-04
JPWO2006109592A1 (ja) 2008-11-06
PL1876236T3 (pl) 2015-01-30
US20230348621A1 (en) 2023-11-02
US20210380717A1 (en) 2021-12-09
JP2012082201A (ja) 2012-04-26
US20100003254A1 (en) 2010-01-07
CA2603264C (en) 2017-03-21
US20250270345A1 (en) 2025-08-28
EP1876236A4 (en) 2009-07-29
US20190112390A1 (en) 2019-04-18
CY1115702T1 (el) 2017-01-25
US20180244800A1 (en) 2018-08-30
EP1876236B1 (en) 2014-08-13
CA2957144C (en) 2020-06-02
NO348522B1 (no) 2025-02-24
US20220213217A1 (en) 2022-07-07
US20170145111A1 (en) 2017-05-25
CA2957144A1 (en) 2006-10-19
PT1876236E (pt) 2014-10-22
US20200277402A1 (en) 2020-09-03
US20250026854A1 (en) 2025-01-23
DK2824183T3 (da) 2020-09-28
JP4917024B2 (ja) 2012-04-18
WO2006109592A1 (ja) 2006-10-19
US20210107995A1 (en) 2021-04-15
EP1876236A1 (en) 2008-01-09
SI1876236T1 (sl) 2014-11-28
EP2824183A1 (en) 2015-01-14
NO20075699L (no) 2008-01-07
JP6055808B2 (ja) 2016-12-27
JP5912436B2 (ja) 2016-04-27
CA2603264A1 (en) 2006-10-19
EP1876236B9 (en) 2015-02-25
EP2824183B1 (en) 2020-07-29
DK1876236T3 (da) 2014-10-20
JP2015015967A (ja) 2015-01-29
US20240190997A1 (en) 2024-06-13
US20120237517A1 (en) 2012-09-20

Similar Documents

Publication Publication Date Title
ES2494921T3 (es) Anticuerpo que sustituye la función del factor VIII de coagulación sanguínea
Iwai et al. Recognition of the high affinity binding site in rev-response element RNA by the human immunodeficiency virus type-1 rev protein
JP2024012523A (ja) 新規な人工核酸分子
JP7093728B2 (ja) 化学的に修飾されたガイドｒｎａを使用する高特異性ゲノム編集
ES2321243T3 (es) Ligandos de acido nucleico que se unen a las adn polimerasas y las inhiben.
CN102703507B (zh) 特异抑制肝细胞CYP2E1基因表达的shRNA慢病毒表达载体及其构建方法与应用
ES2837437T3 (es) Usos diagnósticos, pronósticos y terapéuticos de ARN largos no codificantes para cardiopatías y medicina regenerativa
BR112020008654A2 (pt) composições casz e métodos de uso
Wang et al. RNA Conformation in the Tat− TAR Complex Determined by Site-Specific Photo-Cross-Linking
Satyamoorthy et al. The intracisternal A-particle upstream element interacts with transcription factor YY1 to activate transcription: pleiotropic effects of YY1 on distinct DNA promoter elements
TW201311716A (zh) 用於抑制ｂ型肝炎病毒基因表現之組合物及方法
HUT62658A (en) Reagent and process for modifying expression of gene by imitating rna
EP0542822A1 (en) Viral (hiv) growth inhibition
ES3042109T3 (en) Compositions for controlling cardiac fibrosis and remodeling
JP2006502243A5 (es)
CN113249380A (zh) 靶向covid-19新冠病毒的反义寡核苷酸、natac嵌合分子及其应用
EP0736105A1 (en) Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5786145A (en) Oligonucleotide competitors for binding of HIV RRE to REV protein and assays for screening inhibitors of this binding
JP2019517471A (ja) Ｍｉｒ−３０２前駆体を抗癌薬物としてヒト肺癌を治療するために用いる組成物及び方法
JP2005537028A5 (es)
WO2019196883A1 (zh) 一种激活p21基因表达的方法
US6153382A (en) Viral growth inhibition
Li et al. miR-29c-3p accelerates mucosal repair in dextran sodium sulfateinduced ulcerative colitis mice through the KDM6B/H3K27me3/LDHA Axis
Urata et al. Anti-HIV-1 activity and mode of action of mirror image oligodeoxynucleotide analogue of Zintevir
CN116870197A (zh) 促组织细胞增生重编程因子制剂及用途